Remarkable advancements have been achieved in the treatment of colon and breast cancer, yet an important challenge
persists in combating the mesenchymal-like subtypes of these malignancies, marked by heightened malignancy and
resistance to therapy. Notably, we have pinpointed the pivotal role of the transcription factor ZEB1 in the genesis and
remarkable cellular plasticity of these mesenchymal-like cancer subtypes. Our overarching objective is to specifically
target this particular subset of mesenchymal-like colon and breast cancers, as a pressing medical exigency exists for
innovative therapeutic interventions that can enhance patient outcomes. To this end, we conducted a rigorous screening
of a human cancer EMT model utilizing a sensitive EMT sensor approach in conjunction with a library of chemical
compounds. This extensive screening has culminated in the discovery of a novel anti-EMT compound. This project
endeavors to delve deeper into the characterization of this newfound compound, undertaking a comprehensive
validation process, and assessing its therapeutic potential in treating mesenchymal-like colon and breast cancers. Our
hypothesis posits that a plastistatic therapy approach will induce re-differentiation in these cancers, making them more
amenable to potential combination therapies.